Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Non-Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
45 drugs · 284 active trials
27 drugs · 479 active trials
56 drugs · 2,316 active trials
Outside the funnel: Phase not stated 1 · Withdrawn 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 16 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pidnarulex | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Oct 13, 2026 |
| Talimogene Laherparepvec | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 27, 2017 |
| Therapeutic Glucocorticoid | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Sep 8, 2025 |
| Tovorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | May 29, 2026 |
| Tucatinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 23, 2018 |
| Ipilimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 15 | 0 | — | — | 2003-04 |
| Bevacizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 13 | 0 | — | — | 2001-04 |
| Vinorelbine | Phase 2 | Phase 2 | 0 | 0 | 0 | 11 | 0 | — | — | 2003-12 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2001-04 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2001-01 |
| Dinaciclib | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | 2006-08 |
| Topotecan | Phase 2 | Phase 2 | 0 | 0 | 0 | 7 | 0 | — | — | Jun 2, 1998 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 6 | 0 | — | — | 2012-12 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2010-12 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | 2004-10 |
| Anti-PD1 Monoclonal Antibody | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Sep 10, 2019 |
| Cabozantinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2012-06 |
| Capecitabine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2010-06 |
| Dordaviprone | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | Nov 3, 2015 |
| Imatinib Mesylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2001-08 |
| O6-Benzylguanine | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1999-04 |
| Valproic Acid | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-02 |
| Bimiralisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Nov 12, 2015 |
| Celecoxib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2004-11 |
| Fluorouracil | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2017-12 |
| Galiximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2002-01 |
| Hematopoietic Cell Transplantation | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2001-10 |
| Sorafenib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-11 |
| Tremelimumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | Jul 13, 2016 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-01 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 6, 2016 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 27, 2015 |
| Immunomodulatory Oligonucleotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2014-03 |
| Lorlatinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Sep 28, 2019 |
| Meloxicam | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-10 |
| Pasireotide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-12 |
| Peginterferon Alfa-2b | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 23, 2001 |
| Sonidegib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 17, 2014 |
| Sotrastaurin Acetate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-11 |
| Toripalimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Jun 1, 2020 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-07 |
| Vistusertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2015-10 |
| Amrubicin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-08 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2014 |
| Cetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 12, 2012 |
| Chloroquine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-10 |
| Dacarbazine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 31, 2012 |
| Daromun | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 9, 2023 |
| Eprenetapopt | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 30, 2021 |
| Interferon Alpha-2a | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1997-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.